Marine Compounds and Cancer / / edited by Friedemann Honecker, Sergey A. Dyshlovoy.
The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U(R)), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the l...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2018. |
| Year of Publication: | 2018 |
| Language: | English |
| Physical Description: | 1 online resource (v, 110 pages) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U(R)), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development. |
|---|---|
| Hierarchical level: | Monograph |
| Statement of Responsibility: | edited by Friedemann Honecker, Sergey A. Dyshlovoy. |